BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, December 30, 2025
Home » Authors » Mark McCarty

Articles by Mark McCarty

Washington roundup: InHealth underwrites a survey of industry regarding 510(k)s

Oct. 29, 2010
By Mark McCarty

Washington roundup: FDA warning takes aim at another PACS systems firm

Oct. 28, 2010
By Mark McCarty

Washington roundup: EMEA takes aim at conflicts of interest, seeks transparency

Oct. 27, 2010
By Mark McCarty

Washington roundup: Grassley prodding FDA again over payments to physicians

Oct. 26, 2010
By Mark McCarty

Washington roundup: Health Canada drafts guidance for class III and IV applications

Oct. 25, 2010
By Mark McCarty

India looks to become global player in med-tech industry

Oct. 22, 2010
By Mark McCarty
WASHINGTON – Mavens of the med-tech industry already know they have fans among governments of nations other than the U.S. – thanks in no small part to the higher-than-average wages enjoyed by employees of the industry – but a session held on the last day of AdvaMed 2010, hosted by the Advanced Medical Technology Association (AdvaMed; Washington) made clear that the colossus of the subcontinent has now declared itself a player in the global med-tech sweepstakes. (Medical Device Daily)
Read More

'It depends' the answer to IIB/statutory fix question

Oct. 21, 2010
By Mark McCarty
WASHINGTON – The pace of change at FDA is usually thought of as torpid, but the device and diagnostics industries are concerned that the changes proposed for the 510(k) program might be rapid in coming and hence destructive. (Medical Device Daily)
Read More

Ubl: 510(k) process 'needs tune-up, not a new engine'

Oct. 21, 2010
By Mark McCarty

SGR, cost of PPACA's reforms, omitted in reimbursement talk

Oct. 20, 2010
By Mark McCarty
WASHINGTON – If predictability is the Holy Grail of industry, the search is presumed to be ongoing thanks to, among other things, the uncertainties engendered by the Patient Protection and Affordable Care Act of 2010 (PPACA). (Medical Device Daily)
Read More

Washington roundup: FDA extends public comment period for new user fee schedule

Oct. 19, 2010
By Mark McCarty
Previous 1 2 … 472 473 474 475 476 477 478 479 480 … 576 577 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 29, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 29, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing